Biphasic role of dopamine on female sexual behaviour via D2 receptors in the mediobasal hypothalamus.
Dopamine has been implicated in the control of sexual behaviour, but its role seems quite complex and controversial. The aim of the present experiments was to investigate the effects of dopamine (DA) acting on D2 receptors in the mediobasal hypothalamus (MBH) on sexual behaviour in female sheep. To achieve this, the D2 agonist, quinpirole, was administered bilaterally via microdialysis probes into the MBH of ovariectomized ewes either before or after oestradiol (E2) administration. Quinpirole (100 ng/ml) infused for 6 h just before E2 hastened the onset of oestrus behaviour and the luteinizing hormone surge, whereas the same treatment given 6-12 h or 18-21 h after E2 decreased the intensity of sexual receptivity without affecting LH or prolactin secretion. We then tested the hypothesis that E2 stimulates the onset of oestrus partly by decreasing DA activation of D2 receptors. In this case the D2 antagonists pimozide or spiperone (100 ng/ml) were infused into the MBH via microdialysis probes for 11 h in the absence of E2 administration. A significant number of ewes showed induction of receptivity with both antagonists, although its intensity was significantly lower than that induced by E2. These treatments generally did not significantly alter extracellular concentrations of monoamines or aminoacids although quinpirole modulated the ability of sexual interactions to increase noradrenaline release. These experiments show that DA acts via D2 receptors in the MBH to control female sexual behaviour in a biphasic manner: the onset of sexual motivation and receptivity requiring an initial increase in activation followed by a decrease. This dual action could explain some of the controversies concerning DA action on sexual behaviour.
Fabre-Nys
Claude
C
UMR 6073 INRA/CNRS/Université de Tours. Station de Physiologie de la Reproduction et des Comportements Nouzilly, 37380, France. fabre@tours.inra.fr
Chesneau
Didier
D
de la Riva
Carlos
C
Hinton
Michael R
MR
Locatelli
Alain
A
Ohkura
Satoshi
S
Kendrick
Keith M
KM
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D002956:Citrulline / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D005110:Extracellular Space / Q000378:metabolism; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism; D005998:Glycine / Q000378:metabolism; D006041:Goats; D007033:Hypothalamus, Middle / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D017551:Microdialysis / Q000379:methods; D009638:Norepinephrine / Q000378:metabolism; D010052:Ovariectomy; D010868:Pimozide / Q000494:pharmacology; D011388:Prolactin / Q000097:blood / Q000187:drug effects; D019257:Quinpirole / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D013134:Spiperone / Q000494:pharmacology; D013654:Taurine / Q000378:metabolism; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D015102:3,4-Dihydroxyphenylacetic Acid; D013654:Taurine; D010868:Pimozide; D019257:Quinpirole; D002956:Citrulline; D001224:Aspartic Acid; D012701:Serotonin; D018698:Glutamic Acid; D004958:Estradiol; D013134:Spiperone; D005680:gamma-Aminobutyric Acid; D011388:Prolactin; D007986:Luteinizing Hormone; D005998:Glycine; D004298:Dopamine; D009638:Norepinephrine